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Edited by Jesus AvilaAbstract The serotonin 5-hydroxytryptamine (5-HT4) receptor
is of potential interest for the treatment of Alzheimers disease
because it increases memory and learning. In this study, we
investigated the eﬀect of zinc metalloprotease inhibitors on the
amyloid precursor protein (APP) processing induced by the sero-
tonin 5-HT4 receptor in vitro. We show that secretion of the non-
amyloidogenic form of APP, sAPPa induced by the 5-HT4(e)
receptor isoform was not due to a general boost of the constitu-
tive secretory pathway but rather to its speciﬁc eﬀect on a-secre-
tase activity. Although the h5-HT4(e) receptor increased IP3
production, inhibition of PKC did not modify its eﬀect on sAPPa
secretion. In addition, we found that a secretase activity is regu-
lated by the cAMP-regulated guanine nucleotide exchange fac-
tor, Epac and the small GTPase Rac.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The amyloid precursor protein (APP) is a type I integral
membrane glycoprotein constitutively expressed in many types
of mammalian cells. APP is the precursor of the amyloid b
peptide (Ab), the main component of the senile plaques found
in brains of Alzheimers disease (AD) patients [reviewed in
[1,2]]. Cleavage of APP at the N-terminus of Ab by b-secretase
and at the C-terminus by c-secretase constitutes the amyloido-Abbreviations:ACh, acetylcholine; AD, Alzheimers disease; ADAM, a
disintegrin and metalloprotease; Ab, amyloid b-peptide; APP, amyloid
precursor protein; sAPPa, soluble form of the amyloid precursor
protein; FSK, forskolin; GEF, guanine nucleotide exchange factor;
GPCRs, G protein-coupled receptors; 5-HT, 5-hydroxytryptamine; h5-
HT4, human 5-HT4 receptor; IP3, inositol 1,4,5-trisphosphate; FCS,
foetal calf serum; CHO cells, Chinese hamster ovary cells; SDS, sod-
ium dodecyl sulfate; PKC, protein kinase C; SEAP, secreted placental
alkaline phosphatase; TACE, tumour necrosis factor a converting
enzyme; ADAM17; TAPI, tumour necrosis factor-a protease inhibitor
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doi:10.1016/j.febslet.2005.01.010genic pathway and yields the Ab peptide which easily aggre-
gates in the brain [reviewed in [1]]. Alternatively, the a-
secretase pathway cleaves APP in its extracellular domain
and releases a large soluble N-terminal ectodomain named
sAPPa into the extracellular space. The a cleavage is of phys-
iological interest because secreted sAPPa has neuroprotective
properties and potent memory-enhancing eﬀects [reviewed in
[3]].
Three members of the ADAM family (ADAM stands for a
disintegrin and metalloprotease), ADAM-9, ADAM-10 and
TACE (tumour necrosis factor a converting enzyme,
ADAM17) have been identiﬁed as candidates for the a-secre-
tase activity of APP [reviewed in [4]]. These metalloproteases
are membrane-anchored proteins involved in the proteolytic
cleavage or ‘‘shedding’’ of many transmembrane protein ecto-
domains [6]. They are inhibited by hydroxamic-acid-based zinc
metalloproteases such as batimastat, marimastat, and tumour
necrosis factor-a protease inhibitor (TAPI) [5,6]. The a-secre-
tase cleavage occurs constitutively in all cell lines examined
but can be regulated by G protein-coupled receptors (GPCRs)
[7,8]. Many studies have explored the role of protein kinase C
(PKC) in APP metabolism and there are now some evidence
that constitutive and regulated a-secretase cleavage of APP in-
volved ADAM-10 and TACE [7]. To date, the eﬀects of
cAMP-dependent signalling on the shedding of APP ectodo-
main have not yet been investigated.
The 5-hydroxytryptamine (5-HT4) receptor has gained a lot
of attention for its physiological eﬀects on the brain [9]. This
receptor is positively coupled to adenylyl cyclase and activates
the cAMP-regulated guanine nucleotide exchange factor
(GEF), Epac through the small GTPases Rap1 and Rac [10].
Pharmacological studies have shown that activation of the 5-
HT4 receptor increases memory and learning in rats [9,11].
Further support for a therapeutic potential of 5-HT4 receptor
agonists in the treatment of AD comes from our observations
that the 5-HT4 receptor can regulate APP processing [12]. To
further understand the inﬂuence of the 5-HT4 receptor in this
process, we have examined the eﬀects of a number of metallo-
protease inhibitors on basal and 5-HT4 receptor-regulated
sAPPa release. Experiments were carried out in Chinese ham-
ster ovary (CHO) cells stably expressing the h5-HT4(e) recep-
tor, a neuronal 5-HT4 receptor isoform. In addition, we
analysed the eﬀects of various cAMP analogues as well as Epacblished by Elsevier B.V. All rights reserved.
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tion was measured upon 5-HT4 receptor and Epac activation.2. Materials and methods
2.1. Materials
All media, sera, and antibiotics used in the cell culture were pur-
chased from Life Technologies (Cergy Pontoise, France). The 5-HT4
agonist, cisapride was synthesised in Dr. Sam Sicsics laboratory (BIO-
CIS, CNRS, Chaˆtenay-Malabry, France). The 5-HT4 agonist, renza-
pride, the 5-HT4 receptor antagonist, GR113808, as well as the
5-HT1B receptor antagonist GR127935 were generously given by
GlaxoSmithKline (Harlow, UK). The 5-HT4 agonist, prucalopride
was a gift from Janssen Research Foundation (Beerse, Belgium). 5-HT
was from Aldrich (LIsle dAbeau Chesnes, France). 8-(4-Chloro-phe-
nylthio)-2 0-O-methyladenosine-3 0-5 0-cyclic monophosphate (8-pCPT-
2 0-O-Me-cAMP) was from Biolog Life Science Institute (Bremen,
Germany). BIM1, phorbol 12-myristate 13-acetate (PMA), forskolin
(FSK) and 8-bromo-cyclic AMP (8-bromo-cAMP) were obtained from
Calbiochem (France Biochem, Meudon, France). TAPI-2 was given by
Amgen (Thousand Oaks, CA). Marimastat and batimastat were pro-
vided by GlaxoSmithKline (Harlow, UK).
2.2. Cell culture and transient transfection
CHO cells stably coexpressing the h5-HT4(e) receptor isoform and
APP695 were cultured as previously described [8]. Transient transfec-
tion experiments were performed using jetPEI (Polyplus-transfec-
tion, Illkirch, France) according to the manufacturers instructions.
2.3. Measurement of sAPPa by Western blot
For determination of secreted sAPPa, conﬂuent CHO and IMR32
cell cultures were cultured in 5% dialysed foetal calf serum (FCS)-con-
taining medium overnight and in serum free medium for 4 h, respec-
tively. After drug treatment in serum free medium, media were
centrifuged to remove cell debris and concentrated by ultraﬁltration
(Vivaspin columns, Vivascience, Palaiseau, France). Collected media
were reconstitued in 70 ll of buﬀer consisting of 50 mM Tris, pH
7.4, 5 mM EDTA, and 1 mM phenylmethylsulfonyl ﬂuoride. The pro-
tein amount in each sample was determined with the bicinchoninic acid
assay (Sigma, Saint Quentin Fallavier, France). 70 lg of secreted pro-
teins were run on 8% sodium dodecyl sulfate (SDS) polyacrylamide gel
and secreted sAPPa was detected as previously described [12] by Wes-
tern blotting using the monoclonal antibody 6E10 (Signet Pathology
Systems, Dedham, USA) which is speciﬁc for the a-secretase cleaved
form of human APP. For quantiﬁcation, ﬁlms of representative
experiments were scanned using a Biorad image acquisition system
(Ivry-Sur-Seine, France, gel doc 1000) and fold induction of sAPPa
expression level compared to corresponding controls was calculated.
Western blot experiments were repeated at least three times with iden-
tical results.
2.4. Secreted placental alkaline phosphatase (SEAP) assay
For determination of SEAP activity, CHO cells stably expressing the
h5-HT4(e) receptor isoform were cultured in 96 well-plates. Twenty
four hours after transfection with a recombinant vector encoding the
human SEAP, conﬂuent cells were washed with serum-free medium
and preincubated for 10 min in serum-free medium supplemented with
1 lM GR127935 to block the activity of endogenous 5-HT1B receptor,
and increasing concentrations of 5-HT4 ligands were added for 30 min.
Conditioned supernatants were collected and heated at 65 C for
5 min. Five ll of supernatant was added to 100 ll of phosphatase sub-
strate solution (Sigma, Saint Quentin Fallavier, France) for an incuba-
tion of 30 min at 37 C. SEAP activity was determined by colorimetric
assay at 450 nm.
2.5. Determination of Ab
Two days after plating, cells were cultured in 5% dialysed FCS-con-
taining medium for an overnight period. Then, cells were washed with
serum-free medium, and new fresh medium was added. Cells were trea-
ted with diﬀerent concentrations of 5-HT, or prucalopride, or vehicle
at the beginning of the assay and 24 hs later. After this 48-h period,conditioned media were collected and frozen at 80 C until ELISA
analysis. Total Ab was detected by a electrochemiluminescence assay
with an Origen M8 Analyzer (IGEN Europe Inc., Oxford, UK). The
4G8 antibody (Senetek PLC, Napa, CA) directed against the Ab 17–
24 sequence was ruthenylated with TAG-NHS ester according to the
suppliers instructions (IGEN Europe Inc.) and used in conjunction
with the 6E10-biotinylated antibody (Senetek PLC) directed against
the Ab 5–15 sequence.
2.6. IP3 measurement
Conﬂuent CHO cell cultures were cultured in 5% dialysed FCS-con-
taining medium overnight. At the beginning of the assay, CHO cells
were washed with serum-free medium and preincubated for 10 min
in serum-free medium supplemented with 1 lM GR127935. Then, 5-
HT4 ligands and drugs were added for the indicated time periods.
Upon stimulation, cells were scraped in cold phosphate buﬀer solution
and immediately frozen at 80 C until inositol 1,4,5-trisphosphate
(IP3) was measured using a tritiated radioimmunological kit (Amer-
sham Biosciences, Les Ulis, France).
2.7. Statistical analysis
An unpaired Students t-test was used to calculate diﬀerences be-
tween means; diﬀerences were considered signiﬁcant when P was
<0.05.3. Results
The eﬀects of three inhibitors of zinc metalloproteases,
batimastat, marimastat, and TAPI on the activity of a-secre-
tase were examined in CHO cells stably coexpressing the h5-
HT4(e) receptor isoform and APP695. When CHO cells were
treated with batimastat (10 lM), marimastat (10 lM) or TAPI
(10 lM), activation of the 5-HT4 receptor with 5-HT (1 lM) or
prucalopride (1 lM) failed to increase sAPPa release (Fig. 1A
and B). Similar results with prucalopride were obtained in hu-
man neuroblastoma IMR32 cells, which express endogenous
h5-HT4 receptors (human 5-HT4 receptor, data not shown).
The contribution of metalloprotease in the a cleavage of
APP induced by the 5-HT4 receptor was also investigated by
transfecting ADAM10 constructs. As shown in Fig. 1C, an
inactive form of ADAM10 (ADAM10-DN) [13] inhibited 5-
HT-induced secretion of sAPPa whereas transfection of the
wild-type form of ADAM10 (ADAM-WT) mimicked the stim-
ulating eﬀect of 5-HT on sAPPa secretion (Fig. 1C). Similar
levels of sAPPa were detected in CHO cells transfected with
ADAM-WT in the absence or in the presence of 5-HT (Fig.
1C), probably because the a cleavage of APP reached its max-
imum upon tranfection of ADAM-WT. Moreover, the fact
that ADAM10-DN enhanced sAPPa secretion compared to
mock-transfected cells may be explained by its residual cata-
lytic activity. Altogether these results show that induced sAP-
Pa shedding by 5-HT4 receptor involves zinc metalloproteases.
Next, we investigated whether the constitutive secretory path-
way may be aﬀected by the 5-HT4 receptor. To do this, we used
SEAP which is known to be a marker for the constitutive
secretory pathway [14]. Fig. 1D shows that 5-HT did not sig-
niﬁcantly alter SEAP activity. This result indicates that the
inﬂuence of the 5-HT4 receptor on APP processing is due to
a speciﬁc eﬀect on a-secretase activity rather than a general
boost of the constitutive secretory pathway.
All the C-terminal splice variants of the h5-HT4 receptor are
positively coupled to adenylyl cyclase [15]. Besides cAMP, we
found here that activation of the 5-HT4(e) receptor isoform can
also induce IP3 production. Indeed, increasing concentrations
Fig. 1. Inhibition of 5-HT4 receptor-induced sAPPa release by zinc metalloprotease inhibitors. (A) CHO cells stably expressing the h5-HT4(e)
receptor isoform and the APP695 were pre-incubated with 10 lM of batimastat or marimastat just prior to treatment with 1 lM of 5-HT. After a 30-
min period, sAPPa was detected in the culture medium by immunoblotting. (B) Eﬀect of TAPI on prucalopride (1 lM) induced-sAPPa secretion. The
amounts of secreted sAPPa detected in the media was expressed as fold activation over control. sAPPa expression in untreated control cells was
deﬁned arbitrarily as 1. Results are means ± S.E.M. for three independent experiments. *P < 0.05, **P < 0.01 compared with prucalopride treated
cells (t-test). (C) An inactive form of ADAM10 inhibits 5-HT4 receptor induced sAPPa secretion. CHO cells were transfected with the empty vector
(8 lg), or ADAM-WT (8 lg) or ADAM-DN (8 lg). One day after, cells were stimulated with 1 lM 5-HT for 30 min and sAPPa secretion was
determined as above. Upper panel, a representative Western blot is shown. Lower panel, the quantiﬁcation of the signal is presented as relative
protein expression. The expression in untreated control cells transfected with the empty vector was deﬁned arbitrarily as 1. Results are
means ± S.E.M. for two independent experiments. (D) 5-HT4 receptor activation does not aﬀect SEAP activity. CHO cells were transiently
transfected with 8 lg of plasmid construct encoding the human SEAP. One day later, cells were treated with increasing concentration of 5-HT
(1010–105 M) for 30 min and enzymatic activity was detected in the culture medium by colorimetric assay. Values were expressed as percentage of
the control untreated cells in the same experiment. Results are means ± S.E.M. for two independent experiments performed in duplicates. CT,
untreated control cells.
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(Fig. 2A and B). Similarly, treatment of CHO cells with the
partial 5-HT4 agonists, renzapride (1 lM) or cisapride
(1 lM), increased IP3 accumulation (Fig. 2B). Increase IP3
production is generally accompanied by diacylglycerol produc-
tion which, concomitantly with the release of calcium from
intracellular stores, activates PKC. Activation of PKC has
been shown to favour a-secretase cleavage of APP and this
process involved the ADAM family of metalloproteases
[5,13,16,17]. Therefore, we analysed the potential involvement
of PKC in 5-HT4 receptor regulated a-secretase cleavage. Di-
rect stimulation of PKC by the PMA (1 lM) strongly induced
sAPPa secretion (Fig. 2C, lane 6). The lower migrating band
that appears in PMA-treated cells may result from a diﬀerent
glycosylation state of secreted sAPPa (Fig. 2C, lane 6). Such
a migration proﬁle for sAPPa was observed in other works
[12,17]. The PMA response as well as constitutive a-secretasecleavage of APP were completely blocked when cells were pre-
treated with a pharmacological PKC inhibitor, BIM1 (10 lM)
(Fig. 2C). However, BIM1 failed to block the ability of 5-HT
to stimulate sAPPa secretion (Fig. 2C). Therefore, although
the 5-HT4 receptor enhanced IP3 production, PKC is not in-
volved in 5-HT4 receptor-induced a-secretase cleavage of APP.
Next, we focused our study on the involvement of cAMP
signalling pathway in APP ectodomain shedding. An activator
of adenylyl cyclase, FSK (10 lM), or with 8-Br-cAMP (10 lM)
mimicked the eﬀects of 5-HT since they caused an increase in
the release of sAPPa (Fig. 3A and B). cAMP-induced sAPPa
release was inhibited with batimastat (10 lM) (Fig. 3A), or
TAPI (10 lM) (Fig. 3B), or marimastat (data not shown). This
result indicates that ADAM proteases contribute to cAMP-
regulated a-secretase cleavage of APP. We have recently
shown that the 5-HT4 receptor activates a new signalling path-
way that involves the cAMP-regulated GEF, Epac and the
Fig. 2. 5-HT4 receptor activation enhanced IP3 production but PKC is not involved in 5-HT4 receptor-induced sAPPa secretion. (A) Concentration-
dependent and (B) time-dependent stimulation of IP3 production upon activation of the 5-HT4(e) receptor with various agonists. (A) CHO cells were
treated with increasing concentrations of either 5-HT or prucalopride for 5 min. Data are means ± S.E.M of three experiments performed in
triplicates. *P < 0.05, **P < 0.01, ***P < 0.001 compared with control cells (t-test). (B) Diﬀerences were statistically signiﬁcant upon 1 min treatment
with 5-HT or prucalopride (P < 0.01 and P < 0.001), or 3 min treatment with renzapride or cisapride (P < 0.05, P < 0.01, and P < 0.001) compared to
control cells.j, prucalopride;s, renzapride; d, cisapride; andh, 5-HT. (C) Secreted sAPPa induced by the activation of the 5-HT4(e) receptor is not
inhibited by a pharmacological inhibitor of PKC, BIM1. CHO cells were pre-incubated or not with 1 lM BIM1 for 10 min prior to treatment with
1 lM of 5-HT or PMA. After an additional period of 30 min, sAPPa was detected in the culture medium by immunoblotting. Upper panel, a
representative immunoblot is shown. Lower panel, the amounts of secreted sAPPa detected in the media was expressed as fold activation over
control. sAPPa expression in untreated control cells was deﬁned arbitrarily as 1. Results are means ± S.E.M. for two independent experiments.
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ment of Epac1 and Rac in APP ectodomain shedding. To do
this, we used a Epac-speciﬁc cAMP analogue which does not
activate cAMP-dependent protein kinase, 8-pCPT-2 0-O-Me-
cAMP [18]. As shown in Fig. 3A and B, 8-pCPT-2 0-O-Me-
cAMP (10 lM) strongly enhanced basal release of sAPPa
which was completely blocked in the presence of 10 lMmetal-
loprotease inhibitors. Similarly, transfection of CHO cells with
a constitutive activated form of Epac1 (Epac-DcAMP) or Rac
(RacGV12) increased the cellular release of sAPPa which was
strongly inhibited in the presence of TAPI (10 lM) (Fig. 3C)
or marimastat (10 lM) (data not shown).
In order to elucidate whether the stimulating eﬀect of the 5-
HT4(e) receptor isoform on sAPPa may also aﬀect Ab genera-
tion, total Ab (Ab40 and Ab42) was assayed by ELISA in
CHO cell culture media (Fig. 4A). We did not ﬁnd any concen-
tration-dependent eﬀect of either 5-HT or prucalopride onextracellular Ab compared to vehicle control CHO cells (Fig.
4A). As Epac is one of the main downstream component of
the 5-HT4(e) receptor isoform which is involved in APP pro-
cessing, we also assessed its eﬀect on the production of extra-
cellular Ab. In contrast to what we observed on sAPPa
release (Fig. 3), selective activation of Epac with 10 lM 8-
pCPT-2 0-O-Me-cAMP did not produce any signiﬁcant change
in the levels of extracellular Ab compared to control saline-
treated cells (Fig. 4B).4. Discussion
We showed here that secretion of sAPPa induced by the h5-
HT4(e) receptor was not due to a general boost of the constitu-
tive secretory pathway. In contrast, the zinc metalloprotease
inhibitors, batimastat, marimastat, and TAPI were eﬀective
Fig. 3. cAMP-dependent activation of sAPPa secretion is inhibited by zinc metalloprotease inhibitors in CHO cells. cells were treated with FSK
(10 lM), 8-Br-cAMP (10 lM) or 8-pCPT-20-O-Me-cAMP (10 lM) for 30 min in the absence or presence batimastat (10 lM) (A) or TAPI (10 lM)
(B). sAPPa release was detected in the culture medium by immunoblotting using the 6E10 antibody. (C) Epac1- and Rac-enhanced sAPPa release are
inhibited by TAPI. CHO cells were transiently transfected with vector alone (8 lg), or constitutive activated forms of Epac (Epac-DcAMP) (8 lg), or
RacG12V (8 lg). One day after, cells were treated or not with TAPI (10 lM) for 30 min and sAPPa secretion was assessed by Western blot. A
representative immunoblot is shown. The expression in untreated control cells transfected with the empty vector was deﬁned arbitrarily as 1. Results
are means ± S.E.M. for three independent experiments. *P < 0.05, **P < 0.01, compared with control cells (t-test). Note that the diﬀerences observed
in basal levels of sAPPa in control cells presented in (A), (B) and (C) may be explained by small diﬀerences in cell density between the experiments.
Indeed, cell density has been recently reported to inﬂuence basal and regulated levels of sAPPa in several cell lines [29].
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cating that the receptor regulates the activity of the a secreta-
ses. In our experiments, the metalloproteases inhibitors were
added extemporaneously with 5-HT4 ligands in cell culture
media. Using this protocol, we were able to completely block
5-HT4 receptor-induced sAPPa release. Therefore, the kinetic
of activity of ADAM proteins upon 5-HT4 receptor stimula-
tion seems to parallel the activity of the receptor which reaches
its maximun in terms of cAMP production and amount of
Rac-GTP within 15 min [10]. Moreover, we found that exoge-
nous ADAM-DN inhibited 5-HT- induced sAPPa secretion.
Altogether, these data suggest the involvement of either one
or more a-secretases in the regulation of APP ectodomain
shedding induced by the 5-HT4 receptor.
In addition to its coupling to Gs protein, we report here for
the ﬁrst time that the h5-HT4(e) receptor isoform is able to reg-
ulate IP3 production. Our results are in accordance with a pre-
vious ﬁnding showing that the h5-HT4(b) receptor isoform is
coupled to Gai/o proteins, in addition to its well-documented
coupling to Gas [19]. Such observation is not restricted to
h5-HT4 receptor isoforms since other GPCRs, such as C-ter-
minal splice variants of the prostaglandin EP3, couple to dif-ferent G proteins to activate diﬀerent messenger systems [20].
The fact that a pharmacological inhibitor of PKC, BIM1 failed
to block the eﬀect of 5-HT4 receptor activation on sAPPa
secretion indicates that PKC is not involved in 5-HT4 recep-
tor-induced a-secretase cleavage of APP. However, this does
not exclude the participation of PKC in the constitutive release
of sAPPa since we observed a decrease in the constitutive
secretion of sAPPa in the presence of BIM1 in CHO cells.
Accordingly, the involvement of PKC in sAPPa constitutive
secretion has also been observed in other cellular systems, such
as the NT2N neuronal cell line [17].
Recently, we have proposed a new signalling pathway in
which the small G protein Rac is activated by Rap1 following
cAMP binding to the cAMP-GEF, Epac [10]. Rac belongs to
the Rho family of GTPases which includes Rho, Rac and
Cdc42 and is best known for its role in the modulation of
the actin cytoskeleton [21]. Here we showed that Rac is impli-
cated in a precise cellular function which involves the 5-HT4
receptor and APP ectodomain shedding. Indeed, in this study,
we found that the stimulating eﬀect of FSK and cAMP ana-
logues such as 8-Br-cAMP and 8-pCPT-2Me-cAMP on sAPPa
cleavage was blocked by batimastat and TAPI. Transfection of
Fig. 4. Eﬀect of h5-HT4(e) receptor and Epac activation on Ab
secretion. CHO cells were treated either with increasing concentrations
of 5-HT4 receptor agonists (5-HT or prucalopride) (A) or with 10 lM
of the speciﬁc activator of Epac, 8-pCPT-20-O-Me-cAMP (B). Two
days later, extracellular Ab was assayed by ELISA. Ab content was
expressed as percentage of control cells (CT) (preincubated with saline
vehicle only). Data are means ± S.E.M. of three independent exper-
iments performed in quadruplets. *P < 0.05 compared with control
cells (t-test).
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cAMP analogues on sAPPa secretion, and this was decreased
with the metalloprotease inhibitors. Our results indicate that
Epac and the small G protein Rac may inﬂuence a secretase
activity. In accordance with our data, some metalloproteases
albeit distinct from the ADAM family have been shown earlier
to be regulated by Rac [22].
Our observation raises the question of how the activity of
ADAM proteins is regulated by the small GTPase Rac. It is
possible that ADAM activity is increased following phosphor-
ylation by a kinase. Indeed, it has been shown that ADAM-9 is
phosphorylated in vitro by puriﬁed PKC and in intact cells
treated with phorbol esters [23,24]. With regards to the 5-
HT4 receptor signalling pathway, such a possible candidate
could be the p21-Activated Kinase (PAK) which is a down-
stream eﬀector of Rac. PAK has been shown to be required
for processes involved in neurite formation and axonal guid-
ance [25]. Interestingly, PAK3 has been recently isolated as
an APP-interacting protein [26].
Another interesting aspect arising from this study, was the
eﬀect of the 5-HT4 receptor and its associated signalling path-
way on Ab secretion. We did not observe any eﬀect of 5-HT4(e)
receptor and Epac activation on the extracellular levels of total
Ab. Accordingly, other studies failed to demonstrate any in-
verse correlation between sAPPa secretion and Ab generation
suggesting that the a- and b-secretase pathways may be diﬀer-entially controlled [27]. Recent observations suggest that small
G proteins may be potential candidates to diﬀerentially modu-
late the cleavage pattern of APP. Indeed, inhibition of the
small GTPase Rho has been shown to lower preferentially
the amount of Ab42 [28]. Since, in our experimental condi-
tions, total extracellular Ab was quantiﬁed, we cannot exclude
that Rac may diﬀerentially inﬂuence Ab40 and Ab42 levels.
One could imagine that Rho and Rac have diﬀerential eﬀects
on APP metabolism. Rac could inﬂuence the activity of a-
secretase whereas Rho would be devoted to the regulation of
the c-secretase activity. Therefore, potential therapeutic strat-
egies for the treatment of AD might be directed to modulate
the activity of the small G proteins such as Rho and Rac.
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